Evaluation of infection course in mice induced by L. major in presence of positively charged liposomes containing CpG ODN

Document Type: Research Paper


1 Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran

2 Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran

3 Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran



An inoculation of virulent Leishmania major is known as leishmanization (LZ) which is proven to be the most effective control measure against Cutaneous Leishmaniasis (CL). However, using LZ is restricted due to various side effects such as uncontrolled lesion development. In the present research, the efficacy of cationic nanoliposomes containing CpG oligodeoxynucleotides (CpG ODN) as an improved adjuvant delivery system was studied to diminish the lesion development and infection course of L. major after inoculation into the mice. BALB/c mice were inoculated subcutaneously (SC) with L. major plus empty DSPC, DSPC (CpG ODN), DSPC (Non CpG ODN), empty DMPC, DMPC (CpG ODN), DMPC (Non CpG ODN) or HEPES buffer. The results showed that group of mice received DMPC (CpG ODN) nanoliposomes developed a significantly smaller lesion and showed minimum number of L. major in the spleen and draining lymph nodes. In addition, using DMPC (CpG ODN) liposomes resulted in a Th1 type of immune response with a preponderance of IgG2a isotype which is concurrent with the production of DMPC (CpG) induced IFN-γ in the spleen of the mice. Taken together, the results suggested that immune modulation using DMPC (CpG ODN) nanoliposomes might be a practical approach to improve the safety of LZ


1. Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine. 2005 May 25 ; 23(28): 3642-8.

2. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996 Apr 2; 93(7): 2879-83.

3. Krieg AM, Stein CA. Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev.1995 Winter; 5(4): 241.

4. Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines. 2003 Apr; 2(2): 305-15.

5. Krieg AM. The role of CpG motifs in innate immunity. Current Opinion in Immunology. 2000; 12(1): 35-43.

6. Gursel I, Gursel M, Ishii KJ, Klinman DM. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol. 2001 Sep 15; 167(6): 3324-8.

7. Klinman DM. Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opinion on Biological Therapy .2004; 4(6): 937-46.

8. Badiee A, Jaafari MR, Samiei A, Soroush D, Khamesipour A. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin Vaccine Immunol. 2008 Apr; 15(4): 668-74.

9. Jaafari MR, Badiee A, Khamesipour A, Samiei A, Soroush D, Kheiri MT, et al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine. 2007 Aug 10; 25(32): 6107-17.

10. Alavizadeh SH, Badiee A, Khamesipour A, Jalali SA, Firouzmand H, Abbasi A, et al. The role of liposome-protamine-DNA nanoparticles containing CpG oligodeoxynucleotides in the course of infection induced by Leishmania major in BALB/c mice. Exp Parasitol.  Nov; 132(3): 313-9.

11. Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, Nakagawa S, et al. Positively Charged Liposome Functions as an Efficient Immunoadjuvant in Inducing Immune Responses to Soluble Proteins. Biochemical and Biophysical Research Communications. 1997; 240(3): 793-7.

12. Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine.  2004 May 7; 22(15-16): 1903-13.

13. Chikh GG, Kong S, Bally MB, Meunier JC, Schutze-Redelmeier MP. Efficient delivery of Antennapedia homeodomain fused to CTL epitope with liposomes into dendritic cells results in the activation of CD8+ T cells. J Immunol. 2001 Dec 1; 167(11): 6462-70.

14. Karmali PP, Chaudhuri A. Cationic liposomes as non-viral carriers of gene medicines: Resolved issues, open questions, and future promises. Medicinal Research Reviews. 2007; 27(5): 696-722.

15. Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, Modabber F, et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis--A meta-analysis. Vaccine. 2009; 27(35): 4747-53.

16. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine. 2008 Dec 9; 26(52): 6759-67.

17. Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet. 1998 May 23; 351(9115): 1540-3.

18. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity. The Journal of Experimental Medicine. 1997 November 17, 1997; 186(10): 1623-31.

19. Titus RG, Marchand M, Boon T, Louis JA. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 1985 Sep;7(5): 545-55.

20. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol. 1981 Apr; 126(4): 1614-9.

21. Nadim A, Javadian E, Tahvildar-Bidruni G, Ghorbani M. Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filiales. 1983Aug-Oct; 76(4): 377-83.

22. Rhee EG, Mendez S, Shah JA, Wu C-y, Kirman JR, Turon TN, et al. Vaccination with Heat-killed Leishmania Antigen or Recombinant Leishmanial Protein and CpG Oligodeoxynucleotides Induces Long-Term Memory CD4+and CD8+T Cell Responses and Protection Against Leishmania major Infection. The Journal of Experimental Medicine. 2002 June 17; 195(12): 1565-73.

23. Mendez S, Tabbara K, Belkaid Y, Bertholet S, Verthelyi D, Klinman D, et al. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability. Infect Immun. 2003 Sep; 71(9): 5121-9.

24. Hejazi H, Tasbihi M, Jaafari M, Badiee A, Pestechian N, Javadi A, et al. The Role of Liposomal CpG ODN on the Course of L. major Infection in BALB/C Mice. Iranian J Parasitol. 2010; 5(1): 47-54.

25. Yan W, Chen W, Huang L. Mechanism of adjuvant activity of cationic liposome: Phosphorylation of a MAP kinase, ERK and induction of chemokines. Molecular Immunology. 2007; 44(15): 3672-81.

26. O'Hagan DT. Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord. 2001 Nov; 1(3): 273-86.

27. De Oliveira MC, Boutet V, Fattal E, Boquet D, Grognet J-M, Couvreur P, et al. Improvement of in vivo stability of phosphodiester oligonucleotide using anionic liposomes in mice. Life Sciences. 2000 ;67(13): 1625-37.

28. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000 ;408(6813): 740-5.

29. Moll H, Flohe S, Rollinghoff M. Dendritic cells in Leishmania major-immune mice harbor persistent parasites and mediate an antigen-specific T cell immune response. Eur J Immunol. 1995 Mar; 25(3): 693-9.